Mass balance study of [¹⁴C]SHR0302, a selective and potent JAK1 inhibitor in humans

References

• Amin S, Gabriel SE, Achenbach SJ, Atkinson EJ, Melton LJ III. 2013. Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study. J Rheumatol. 40(10):1669–1676.
   PubMed Web of Science ®Google Scholar
• Annal of the ICRP. 1991. 1990 Recommendations of the International Commission on Radiological Protection. Ann. ICRP. 21(1–3):201.
   Google Scholar
• Avci AB, Feist E, Burmester GR. 2021. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology. 60(Suppl 2):ii11–ii16.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M, Poursac N. 2013. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 9(6):753–761.
   PubMed Web of Science ®Google Scholar
• Bertsias G. 2020. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. Mediterr J Rheumatol. 31(Suppl 1):105–111.
   PubMedGoogle Scholar
• Binari R, Perrimon N. 1994. Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Genes Dev. 8(3):300–312.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Pope JE. 2017. Novel treatment strategies in rheumatoid arthritis. Lancet. 389(10086):2338–2348.
   PubMed Web of Science ®Google Scholar
• Cheng H, Yu J, Yang C, Zhang N, Fan Z, Zhang X, Wang J, Wang Z, Zhong DF, He JX, et al. 2022. Absorption, distribution, metabolism, and excretion of [(14)C]TPN729 after oral administration to rats. Xenobiotica. 52(1):79–90.
   PubMed Web of Science ®Google Scholar
• Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C. 2014. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 42(4):759–773.
   PubMed Web of Science ®Google Scholar
• Firestein GS. 2014. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 16(3):114.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 367(6):495–507.
   PubMed Web of Science ®Google Scholar
• Gu YJ, Sun WY, Zhang S, Li XR, Wei W. 2016. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells. Int J Mol Med. 38(3):903–911.
   PubMed Web of Science ®Google Scholar
• He YF, Liu Y, Yu JH, Cheng H, Odilov A, Yang FP, Tian GH, Yao XM, Duan HQ, Yu CY, et al. 2023. Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. Acta Pharmacol Sin. 44(1):221–233.
   PubMed Web of Science ®Google Scholar
• Hop CE, Wang Z, Chen Q, Kwei G. 1998. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 87(7):901–903.
   PubMed Web of Science ®Google Scholar
• Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, et al. 2017. Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther. 19(1):251.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. 2012. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 12(4):464–470.
   PubMed Web of Science ®Google Scholar
• Krishnaswami S, Boy M, Chow V, Chan G. 2015. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 4(2):83–88.
   PubMed Web of Science ®Google Scholar
• Kvien TK, Glennas A, Knudsrod OG, Smedstad LM, Mowinckel P, Forre O. 1997. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand J Rheumatol. 26(6):412–418.
   PubMed Web of Science ®Google Scholar
• Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, Stock TC. 2016. Extended-Release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 56(11):1362–1371.
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. 2015. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 11(12):693–704.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, et al. 2018. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2:23.
   PubMedGoogle Scholar
• Penner N, Klunk LJ, Prakash C. 2009. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 30(4):185–203.
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. 2008. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 11(2):81s–110s.
   PubMed Web of Science ®Google Scholar
• Rosillo MA, Sanchez-Hidalgo M, Sanchez-Fidalgo S, Aparicio-Soto M, Villegas I, Alarcon-de-la-Lastra C. 2016. Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. Eur J Nutr. 55(1):315–325.
   PubMed Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, et al. 1995. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 270(5237):797–800.
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. 2014. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 54(12):1354–1361.
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. 2015. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 17(1):212.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, et al. 2016. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. 2009. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol. 22(2):267–279.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, et al. 2017. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Strehl C, Buttgereit F. 2013. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 380(1-2):32–40.
   PubMed Web of Science ®Google Scholar
• Sun X, He Q, Yang J, Wang A, Zhang F, Qiu H, Zhou K, Wang P, Ding X, Yuan X, et al. 2021. Preventive and therapeutic effects of a novel JAK inhibitor SHR0302 in acute graft-versus-host disease. Cell Transplant. 30:9636897211033778.
   Web of Science ®Google Scholar
• Taylor PC. 2019. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology. 58(Suppl 1):i17–i26.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Abdul Azeez M, Kiriakidis S. 2017. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 26(10):1181–1187.
   PubMed Web of Science ®Google Scholar
• Tian J, Lei P, He Y, Zhang N, Ge X, Luo L, Yan S, Diao X. 2021. Absorption, distribution, metabolism, and excretion of [14C]NBP (3-n-butylphthalide) in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 1181:122915.
   PubMed Web of Science ®Google Scholar
• US FDA. 2019. Olumiant® package insert. [accessed 2019 Dec 13]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf.
   Google Scholar
• US FDA. 2020. Safety testing of drug metabolites. [accessed 2020 Apr 30]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites.
   Google Scholar
• US FDA. 2021. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. [accessed 2021 Dec 7]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
   Google Scholar
• US FDA. 2022. Code of Federal Regulations (CFR) – Title 21—Food and Drugs, Part 361.1. Radioactive drugs for certain research uses. [accessed 2022 Nov 29]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=361&showFR=1.
   Google Scholar
• Vaddi K, Luchi M. 2012. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy. Expert Opin Investig Drugs. 21(7):961–973.
   PubMed Web of Science ®Google Scholar
• Veeravalli V, Dash RP, Thomas JA, Babu RJ, Madgula LMV, Srinivas NR. 2020. Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf. 43(8):711–725.
   PubMed Web of Science ®Google Scholar
• Vree TB, Van Ewijk-Beneken Kolmer EW, Verwey-Van Wissen CP, Hekster YA. 1994. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. Int J Clin Pharmacol Ther. 32(10):550–558.
   PubMed Web of Science ®Google Scholar
• Wang X, He X, Zhang CF, Guo CR, Wang CZ, Yuan CS. 2017. Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats. Biomed Pharmacother. 89:887–893.
   PubMed Web of Science ®Google Scholar
• Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L, et al. 2016. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 83(5):525–532.
   PubMed Web of Science ®Google Scholar
• Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, et al. 2017. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 49(2):105–138.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang Y. 2008. An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. J Mass Spectrom. 43(9):1181–1190.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Pan J. 2021. Immunopathogenic mechanisms of rheumatoid arthritis and the use of anti-inflammatory drugs. Intractable Rare Dis Res. 10(3):154–164.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, et al. 2021. Efficacy and safety of SHR0302, a highly selective janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase ii randomized clinical trial. Am J Clin Dermatol. 22(6):877–889.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhang H, Liu M, Li G, Ma S, Zhang Z, Lin H, Zhan Y, Chen Z, Zhong D, et al. 2022. Pharmacokinetics, mass balance, and metabolism of the novel urate transporter 1 inhibitor [14C]HR011303 in humans: metabolism is mediated predominantly by UDP-glucuronosyltransferase. Drug Metab Dispos. 50(6):798–808.
   PubMed Web of Science ®Google Scholar
• Zheng YD, Zhang H, Zhan Y, Bian YC, Ma S, Gan HX, Lai XJ, Liu YQ, Gong YC, Liu XF, et al. 2021. Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin. 42(9):1535–1546.
   PubMed Web of Science ®Google Scholar
• Zhu M, Ma L, Zhang D, Ray K, Zhao W, Humphreys WG, Skiles G, Sanders M, Zhang H. 2006. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos. 34(10):1722–1733.
   PubMed Web of Science ®Google Scholar